Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Non-alcoholic Steatohepatitis: Update Bulletin [December 2015]

Product Code:
596200390
Publication Date:
December 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events with the potential to shape the treatment of non-alcoholic steatohepatitis (NASH). Topics covered include KOL insight on the results of a Phase II study of Conatus Pharmaceuticals’ caspase protease inhibitor, emricasan, in patients with compensated cirrhosis and portal hypertension, KOL views on the design of Genfit’s Phase III study for elafibranor (GFT505), what KOLs think of the results of Intercept’s/Dainippon Sumitomo Pharma’s Phase II study evaluating obeticholic acid in Japanese patients, how KOLs perceive the potential of Pharmaxis’ PXS-4728A, including specific safety concerns, KOL opinions on the potential of Immuron’s IMM-124E, including its novel mechanism of action.

Key Questions Answered in this Update Bulletin:

  • How do KOLs perceive the results of a Phase II study of Conatus Pharmaceuticals’ caspase protease inhibitor emricasan, in patients with compensated cirrhosis and portal hypertension?
  • What are KOLs’ views on the design of Genfit’s Phase III study for elafibranor (GFT505)?
  • What is the KOL reaction to the results of Intercept/Dainippon Sumitomo Pharma’s Phase II study evaluating obeticholic acid in Japanese patients?
  • How do KOLs perceive the potential of Pharmaxis’ PXS-4728A?
  • Do KOLs harbour any reservations regarding PXS-4728A’s safety profile?
  • What are KOLs’ opinions on the potential of Immuron’s IMM-124E?
  • What concerns do KOLs raise regarding IMM-124E’s mechanism of action?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved